Analyze Diet
Equine veterinary journal. Supplement1992; (11); 45-51; doi: 10.1111/j.2042-3306.1992.tb04772.x

Pharmacokinetics and metabolism of intravenous doxapram in horses.

Abstract: The pharmacokinetics and metabolism of doxapram in horses administered intravenous (iv) doses of 0.275, 0.55 and 1.1 mg doxapram/kg bodyweight (bwt) were investigated. Plasma doxapram concentrations decreased rapidly after drug administration and the disappearance of doxapram from plasma was best described by a polyexponential equation. Median values of total body clearance were 10.9, 10.6 and 10.9 ml/min/kg bwt for the three doses and were independent of dose. The steady-state volume of distribution was approximately 1,200 ml/kg bwt and the median biological half-life ranged from 121 to 178 mins. Plasma protein binding of doxapram ranged from 76.0 to 85.4 per cent. The blood:plasma doxapram concentration ratio was approximately 0.8 and the affinity of the red blood cells for doxapram ranged from 2.0 to 2.8 indicating sequestration of doxapram in erythrocytes. Renal clearance of doxapram was a minor route of elimination. Metabolic clearance of doxapram appeared to be a major route of elimination. Four metabolites of doxapram were isolated from urine and were identified. The metabolites were: a) 1-ethyl-4-[(2-hydroxyethyl) amino]ethyl-3,3-diphenyl-2-pyr-rolidinone, b) a glucuronic acid or sulphuric acid conjugate of 1-ethyl-3-(hydroxyphenyl)-4-(2-morpholinoethyl)-3-phenyl-pyrrolidinone, c) 3,3-diphenyl-4-(2-morpholinoethyl)-2-pyrrolidinone and d) 1-(2-hydroxyethyl)-3,3-diphenyl-4-(2-morpholinoethyl)-2-pyr-rolidinon e. The rapid disappearance of doxapram from plasma immediately after iv administration was attributed to redistribution of the drug from plasma to other tissues. The short duration of clinical effect from doxapram may be attributed to redistribution of the drug from plasma and other well-perfused tissues, such as the brain, to less well-perfused tissues such as the skeletal muscles and adipose tissue. Continuous or repeated administration of doxapram could prolong the duration of clinical effect because re-distribution is less important as steady-state conditions are approached.
Publication Date: 1992-02-01 PubMed ID: 9109960DOI: 10.1111/j.2042-3306.1992.tb04772.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research examines how doxapram, a drug administered to horses, is absorbed, distributed, metabolized, and excreted from the body, while also determining its physical effects on horses of varying weights and dosages.

Research Detail

The study explores the pharmacokinetics and metabolism of Doxapram in horses. Pharmacokinetics deals with how a drug is absorbed, distributed, metabolized, and excreted in the body. Thus, the research offers important insights into the processing of Doxapram by equine organisms.

  • Doxapram was administered intravenously to the horses in doses of 0.275, 0.55, and 1.1 mg/kg body weight.
  • Plasma concentrations of the drug decreased rapidly following administration. This means that the body was quickly processing and removing the drug from the bloodstream.
  • The research found that the rate at which the drug was cleared from the body was largely consistent across all three doses, with median values of total body clearance being 10.9, 10.6, and 10.9 ml/min/kg respectively.
  • The drug was distributed throughout the body, showing a steady-state volume of distribution of around 1,200 ml/kg.
  • The half-life of the drug, the time it takes for the amount of drug in the body to be cut by half, ranged from 121 to 178 mins.

Binding and Elimination

Doxapram activity was also evaluated in terms of its protein binding characteristics and its elimination routes:

  • Protein binding determines how long a drug remains in the body; in this case, it ranged from 76 to 85.4 per cent, which is relatively high.
  • The blood-to-plasma concentration ratio of the drug was around 0.8, which indicates a high level of drug permeability across the blood-brain-barrier (BBB).
  • The renal clearance or elimination of the drug via the kidneys was found to be a minor route of elimination, indicating that the drug is not majorly excreted through urine.
  • On the other hand, the metabolic clearance of Doxapram was found to be a major route of elimination, suggesting that the drug is primarily processed and removed by the liver.

Metabolites and Effect

The study also identified four metabolites resulted when the drug was broken down:

  • It was found that the rapid disappearance of Doxapram from plasma was due to the redistribution of the drug from the plasma to other tissues. This redistribution also accounts for the short duration of the clinical effect of the drug.
  • However, it was also noted that continuous or repeated administration of doxapram could prolong the duration of its clinical effect, as re-distribution would become less important as body reaches a steady-state with these conditions.

Cite This Article

APA
Sams RA, Detra RL, Muir WW. (1992). Pharmacokinetics and metabolism of intravenous doxapram in horses. Equine Vet J Suppl(11), 45-51. https://doi.org/10.1111/j.2042-3306.1992.tb04772.x

Publication

NlmUniqueID: 9614088
Country: United States
Language: English
Issue: 11
Pages: 45-51

Researcher Affiliations

Sams, R A
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University Colmbus 43210, USA.
Detra, R L
    Muir, W W

      MeSH Terms

      • Adipose Tissue / metabolism
      • Animals
      • Blood Proteins / metabolism
      • Brain / metabolism
      • Central Nervous System Stimulants / administration & dosage
      • Central Nervous System Stimulants / metabolism
      • Central Nervous System Stimulants / pharmacokinetics
      • Dose-Response Relationship, Drug
      • Doxapram / administration & dosage
      • Doxapram / metabolism
      • Doxapram / pharmacokinetics
      • Erythrocytes / metabolism
      • Female
      • Half-Life
      • Horses / metabolism
      • Injections, Intravenous / veterinary
      • Male
      • Muscle, Skeletal / metabolism
      • Protein Binding
      • Tissue Distribution

      Citations

      This article has been cited 1 times.
      1. Kraft M, Foerster KI, Wiedmann F, Sauter M, Paasche A, Blochberger PL, Yesilgöz B, L'hoste Y, Frey N, Haefeli WE, Burhenne J, Schmidt C. Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue.. Pharmaceutics 2022 Mar 31;14(4).
        doi: 10.3390/pharmaceutics14040762pubmed: 35456597google scholar: lookup